Form 4: Emergent BioSolutions SVP Acquires Shares and Stock Options

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions, reports acquisition of shares and stock options.

Summary

• Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions Inc., filed a Form 4.
• The filing reports the acquisition of 62,500 shares of common stock and 62,500 employee stock options on March 6, 2025.
• The common stock was acquired through restricted stock units granted under the company's Stock Incentive Plan.
• These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant.
• The employee stock options, with an exercise price of $5.8, also vest in three equal installments beginning on the day prior to the anniversary date of the grant and expire on March 5, 2032.
• Following the reported transactions, Williams beneficially owns 86,335 shares of common stock and 210,114 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions, which doesn't inherently suggest positive or negative sentiment.

Positives

• The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units and employee stock options vest over time, contingent on continued service with the company.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates